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Neurofibromatosis 1 (NF1) is an autosomal genetic disease caused by mutations in the 
NF1 gene.1 Although clinical manifestations of NF1 are variable between individuals, 
most of the patients develop cutaneous neurofibromas. We have already shown that the 
number of cutaneous neurofibromas significantly increases with age.2 It is desirable to 
treat cutaneous lesions before a serious condition develops. However, patients are often 
reluctant to show the lesion on the trunk and it is arduous to evaluate the severity of 
cutaneous manifestations. Therefore, we conducted a case series study to establish a 
method for estimating the number of cutaneous neurofibromas. 
We investigated the number of cutaneous neurofibromas in 47 NF1 patients with more 
than 10 neurofibromas (16 men and 31 women; average age, 41.1 years; age range, 7-79 
years) at the Dermatology Department of Tottori University Hospital from 2014 to 2017. 
All of the patients fulfilled the criteria for a diagnosis of NF1 by National Institutes of 
Health in 1988.3 The study protocol was approved by the Ethics Committee of Tottori 
University Hospital. We counted the number of cutaneous neurofibromas (> 5 mm in 
diameter) at the 4 divisions of the body surface area, the head & neck, trunk, and upper 
and lower extremities, by visual judgment. A fused tumor was counted as one tumor. 
Subcutaneous neurofibromas were not counted in this study. 





(56.8%), followed by the lower extremities (16.7%), upper extremities (15,7%), and head 
& neck (10.8%) (see Table S1). To construct a simple method for estimating total number 
of cutaneous neurofibromas, we conducted regression and correlation analyses. The 
estimated regression lines are presented in Fig. 1. The correlation coefficients between 
the number of cutaneous neurofibromas at each division and the total number of 
cutaneous neurofibromas were R = 0.84 (95%CI: 0.73, 0.91; P < 0.001) for the head & 
neck, R = 0.96 (95%CI: 0.94, 0.98; P < 0.001) for the trunk, R = 0.96 (95%CI: 0.94, 0.98; 
P < 0.001) for the upper extremities and R = 0.93 (95%CI: 0.88, 0.96; P < 0.001) for the 
lower extremities. 
We proposed for the first time a simple method for estimating the total number of 
cutaneous neurofibromas in NF1 from any sites. At first, we considered that it would be 
possible to predict the total number of neurofibromas from the number at the head & neck. 
However, it was not easy to count the exact number on the scalp covered by hair. We 
consider the upper extremities to be the most appropriate sites for estimation without 
hesitation by the patient. Cunha et al. reported a technique using paper frames on the back, 
abdomen and thigh with a specific formula to quantify cutaneous neurofibromas.4 
However, their method is not simple compared to our method because they have to count 





another quantitative method to investigate the state of cutaneous neurofibromas,5 but is 
not practical because of the cost effectiveness in daily medical examinations.  
There is a limitation in our study. Our method may not be applicable if there is extremely 
large number of neurofibromas because it is difficult to count the number accurately due 
to numerous fused tumors. In addition, it is not possible to count subcutaneous 
neurofibromas from the surface. Nevertheless, our proposed method will be useful for 
physicians to estimate the severity of cutaneous neurofibromas. The appropriate 
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Figure 1 Scatter plot of the total number of cutaneous neurofibromas versus the number 
of those at the head & neck (a), trunk (b), upper extremities (c) and lower extremities (d).  
 
